Loading...

ABBV ABBVIE INC Earnings Reports 8-K Filing

BBV

BBV

ABBVIE INC

(ABBV)

2026 8-K

Annual Meeting Results

Financial Results Update

Earnings Guidance Update

Debt Offering Completion

Debt Offering Announcement

Financial Results Announced

Earnings Guidance Update

Financial Results Release

Earnings Guidance Update

Litigation Settlement

Financial Statements

Earnings Releases

Financial Statements

Earnings Guidance

Senior Notes Offering

Leadership Change

Credit Agreement

Financial Results

Impairment Charge

Earnings Guidance

Management Change

Q3 Financial Results

Earnings Guidance

By-law Amendment

Earnings Reports

Earnings Guidance

Appointment of CEO

Earnings Reports

Earnings Guidance

Underwriting Agreement for ...

Management Change

Acquisition of ImmunoGen, Inc.

Financial Results Announcement

Earnings Guidance

Acquisition Agreement

Acquisition Agreement

Financial Results Announcement

Board Expansion and New Dir...

Earnings Guidance

Earnings Reports

Appointment of Officer

Earnings Reports

Earnings Guidance

Credit Agreement Amendment

Financial Results Announcement

Investor Presentation

Earnings Guidance

External Links:

AbbVie Inc. reported an expected expense of $744 million for acquired IPR&D, negatively impacting Q1 2026 earnings by $0.41 per share. The adjusted diluted earnings per share for 2026 is projected between $13.96 and $14.16, reflecting this expense.

AI Assistant

ABBVIE INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.